Ungrungseesopon N, Wongtanasarasin W. Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials. World J Methodol 2022; 12(4): 319-330 [PMID: 36159095 DOI: 10.5662/wjm.v12.i4.319]
Corresponding Author of This Article
Wachira Wongtanasarasin, MD, Attending Doctor, Department of Emergency Medicine, Faculty of Medicine, Chiang Mai University, 110 Intavarorot Street, Sriphum, Chiang Mai 50200, Thailand. wachir_w@hotmail.com
Research Domain of This Article
Emergency Medicine
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jul 20, 2022; 12(4): 319-330 Published online Jul 20, 2022. doi: 10.5662/wjm.v12.i4.319
Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials
Nat Ungrungseesopon, Wachira Wongtanasarasin
Nat Ungrungseesopon, Wachira Wongtanasarasin, Department of Emergency Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
Wachira Wongtanasarasin, Department of Emergency Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA
Author contributions: Ungrungseesopon N and Wongtanasarasin W designed the protocol, contributed to data collection and analysis, and wrote the first draft of the manuscript; Wongtanasarasin W edited and revised the manuscript; both authors read and critically reviewed the final version of the manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2021 Checklist, and the manuscript was prepared and revised according to the PRISMA 2021 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wachira Wongtanasarasin, MD, Attending Doctor, Department of Emergency Medicine, Faculty of Medicine, Chiang Mai University, 110 Intavarorot Street, Sriphum, Chiang Mai 50200, Thailand. wachir_w@hotmail.com
Received: February 4, 2022 Peer-review started: February 4, 2022 First decision: April 11, 2022 Revised: April 26, 2022 Accepted: July 11, 2022 Article in press: July 11, 2022 Published online: July 20, 2022 Processing time: 165 Days and 12.9 Hours
ARTICLE HIGHLIGHTS
Research background
Metoclopramide may be used to treat people suffering from acute migraine. However, no comprehensive investigation on this issue has been recorded. This review will provide more solid evidence for the use of metoclopramide in treating acute migraine.
Research motivation
Metoclopramide was considered the “probably effective drug”, even though several studies showed the efficacy of metoclopramide monotherapy. It has been investigated that the efficacy of metoclopramide was neither inferior to sumatriptan nor opioid. Moreover, apart from the efficacy aspect, metoclopramide showed superiority in other aspects, such as lower adverse severe effects and lower addiction rates.
Research objectives
The objective of this review was to investigate the efficacy of intravenous metoclopramide with other therapies in migraine attack treatment in an emergency department (ED).
Research methods
We conducted a systematic review and meta-analysis of randomized controlled trials.
Research results
The administration of received intravenous metoclopramide was an effective treatment for migraine headache in adults, compared with placebo. However, the benefit of metoclopramide was not superior to other drugs.
Research conclusions
Metoclopramide is more effective than placebo in treating migraine in the ED. Although its effectiveness was not observed on other medications, clinicians may select metoclopramide as one of the first line treatments for acute migraine.
Research perspectives
Despite the observed tendency of decreased side effects, the effectiveness of metoclopramide compared to other regimens is poorly understood. More research on this area is needed to treat migraine in acute care settings effectively.
